CME Webcast Teaches Physicians About Skin Cancer

OSUWexnerbloglogo2014 CME Webcast Teaches Physicians About Skin Cancer. In the 215 years since Laennec discovered melanoma, we have learned an enormous amount about this malignancy and how to best treat it. On this CME webcast, we’re going to update you on the latest information. Joining our moderator are two skin cancer specialists from the James Cancer Hospital. Dr. Joal Beane is a surgical oncologist and Assistant Professor of Surgery at the Ohio State University. And Dr. Carlo Contreras is an Associate Professor of Surgery, also from the OSU Division of Surgical Oncology.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: Describe at least two advantages of neoadjuvant therapy in patients with resectable Stage III/IV melanoma; List the 2 main classes of neoadjuvant therapy in patients with resectable Stage III/IV melanoma; and UNDERSTAND the diagnosis and management of cutaneous melanoma.

You’ll also learn about the following:

  • Subtypes of melanoma
  • Evaluation and diagnosis
  • Indications for referral
  • Role of metastasectomy in advanced melanoma

You can find this and many other MedNet21 programs on the OSU – CCME website.
Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Educates Learners on Lung Cancer Staging

OSUWexnerbloglogo2014 CME Webcast Educates Learners on Lung Cancer Staging. On this program, we’re going to update you on the approach to lung cancer staging. Joining on moderator is our lung cancer expert from the Division of Hematology and Medical Oncology, Clinical Instructor of Internal Medicine, Dr. Jean Bustamante Alvarez.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: RECOGNIZE the importance of lung cancer staging and the need for a multidisciplinary approach; and IDENTIFY the minimally necessary studies that will be necessary to stage a patient with lung cancer.

You’ll also learn about the following:

  • Racial disparities in lung cancer diagnosis and survival
  • Staging small cell lung cancer
  • Surgery versus stereotactic ablative radiotherapy
  • Stereotactic ablative radiotherapy
  • When PET-CT can miss lung cancer

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

On-line CME Webcast Teaches on Prostate Cancer Screening

OSUWexnerbloglogo2014 On-line CME Webcast Teaches on Prostate Cancer Screening. On this CME webcast, we’ll be examining the conundrum of prostate cancer screening. Joining our moderator in the studio is urologic oncologist and Assistant Professor of Urology, Dr. Shawn Dason.

 

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the rationale, benefits, and harms of prostate cancer screening; and DEVELOP an approach for prostate cancer screening in a primary care setting.

You’ll also learn about the following:

  • Prostate cancer risk factors
  • The problem with the PSA
  • False positive PSAs
  • False negative PSAs
  • Interpreting the PSA trajectory over time
  • The urologist’s approach to an elevated PSA
  • Common prostate cancer treatments and their complications

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Teaches on Pancreatic Cancer

OSUWexnerbloglogo2014 CME Webcast Teaches on Pancreatic Cancer. One out of 64 people in the United States will die of pancreatic cancer; it is the 4th leading cause of cancer death. On this CME webcast, we are going to take a look at pancreatic cancer: its causes, its diagnosis, and its treatment. We’re pleased to welcome today’s guest. Dr. Mary Dillhoff is a surgical oncologist and Assistant Professor of Surgery here at the Ohio State University.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: IDENTIFY and learn the types of premalignant pancreas cyst and when surgical referral or further work up is indicated; and DESCRIBE work up and staging or pancreatic cancer and the treatment options.

You’ll also learn about the following:

  • Pancreatic cancer survival
  • Screening for pancreatic cancer
  • Medical management issues after a Whipple procedure
  • Post-op cancer follow up

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Discusses New Therapies for Lung Cancer

OSUWexnerbloglogo2014 CME Webcast Discusses New Therapies for Lung Cancer. On this CME webcast, we’re going to update you on the medical management of lung cancer and focus on non-small cell lung cancer. Joining our moderator in the studio is medical oncologist at the James Cancer Hospital and Professor of Internal Medicine from the Ohio State University, Dr. David Carbone.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: Review some of the latest practice-changing findings in the management of lung cancer; and Understand the basic principles of workup and initial lung cancer management decisions.

You’ll also learn about the following:

  • Classifying non-small cell lung cancer
  • Common side effects of driver-targeted therapies
  • What the primary care physician needs to know about co-managing patients taking driver-targeted therapy

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.